All stock lists
Standard Biotools Inc. (NASDAQ:LAB)
US · Delayed Price · Currency is USD
0.60-0.01 (-1.02%)
Insider Score
––Not scored
LAB Insider Score
Insiders here have filed 4 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
LAB analyst forecast
Best analysts covering LAB
No firm covering LAB has enough calls with a finished 1Y holding period to rank yet.
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
LAB analyst ratings
| Analyst | Firm | Rating | Price target | Upside | Action | Date |
|---|---|---|---|---|---|---|
| — | TD Cowen | Hold | — | — | Reiterated | 2025-11-05 |
| — | Keybanc | Sector Weight | — | — | Downgraded | 2025-02-27 |
| — | TD Cowen | Buy | — | — | Reiterated | 2024-10-31 |
| — | TD Cowen | Buy | — | — | Reiterated | 2024-08-01 |
| — | UBS | Buy | — | — | Reiterated | 2020-08-26 |
| — | UBS | Buy | — | — | Reiterated | 2020-08-09 |
| — | Janney Montgomery Scott | Neutral | — | — | Downgraded | 2019-11-05 |
| — | UBS | Buy | — | — | Upgraded | 2019-10-17 |
| — | Janney Montgomery Scott | Buy | — | — | Upgraded | 2019-01-02 |
| — | Piper Sandler | Overweight | — | — | Upgraded | 2018-11-01 |
| — | Deutsche Bank | Buy | — | — | Reiterated | 2016-02-04 |
| — | Mizuho | Buy | — | — | Upgraded | 2016-02-04 |
| — | Cowen & Co. | Market Perform | — | — | Downgraded | 2016-01-19 |
| — | Cantor Fitzgerald | Buy | — | — | Upgraded | 2015-11-01 |
| — | Cantor Fitzgerald | Buy | — | — | Upgraded | 2015-10-29 |
| — | Cowen & Co. | Outperform | — | — | Reiterated | 2015-10-01 |
| — | Piper Sandler | Neutral | — | — | Downgraded | 2015-08-06 |
| — | Mizuho | Neutral | — | — | Downgraded | 2015-05-07 |
| — | Leerink Swann | Outperform | — | — | Reiterated | 2015-05-07 |
| — | Leerink Swann | Outperform | — | — | Reiterated | 2015-03-04 |
| — | Cowen & Co. | Outperform | — | — | Upgraded | 2015-01-19 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2014-05-05 |
| — | Leerink Swann | Outperform | — | — | Upgraded | 2014-04-13 |
| — | Cowen & Co. | Market Perform | — | — | Downgraded | 2014-02-06 |
| — | Leerink Swann | Market Perform | — | — | Downgraded | 2013-04-28 |
| — | Mizuho | Neutral | — | — | Downgraded | 2012-10-08 |
LAB earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-24 | -0.03 | 0.06 | $18.5M | $23.8M |
| 2026-05-05 | -0.02 | -0.02 | $17.8M | $21.1M |
| 2026-08-05 | -0.01 | -0.07 | $20.8M | $20.1M |
| 2026-11-03 | -0.02 | 0.00 | $18.8M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.